|
Persistent Identifier
|
perma:LIST.W2OCQV |
|
Publication Date
|
2026-07-06 |
|
Title
| Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe [* Cross-Reference *] |
|
Other Identifier
| https://doi.org/10.1182/bloodadvances.2025017081
OpenAlex ID: https://openalex.org/W4414490680 |
|
Author
| Elise R. A. Pennings (Amsterdam Neuroscience, Amsterdam University Medical Centers, International Myeloma Foundation, Cancer Center Amsterdam, Amsterdam University of Applied Sciences, University of Amsterdam, Erasmus University Rotterdam) - ORCID: https://orcid.org/0000-0001-7674-2148
Anne M. Spanjaart (Amsterdam Neuroscience, Amsterdam University Medical Centers, International Myeloma Foundation, Cancer Center Amsterdam, University of Amsterdam) - ORCID: https://orcid.org/0000-0003-0167-6021
Frederick W. Thielen (Erasmus University Rotterdam) - ORCID: https://orcid.org/0000-0002-0312-5891
Simone Oerlemans (Netherlands Comprehensive Cancer Organisation) - ORCID: https://orcid.org/0000-0003-1595-7262
Anna Fleischer (Augenklinik Universitätsklinikum Würzburg) - ORCID: https://orcid.org/0009-0009-8760-3931
Carmen Sanges (Augenklinik Universitätsklinikum Würzburg) - ORCID: https://orcid.org/0009-0000-1184-387X
María Gomes da Silva (Instituto Português de Oncologia Francisco Gentil) - ORCID: https://orcid.org/0000-0002-6993-2450
Yolanda Cabrerizo (European Hematology Association)
Pacôme Lecot (Institut National du Cancer) - ORCID: https://orcid.org/0000-0001-6338-8784
Lutgart Roux-Opstaele (Institut National du Cancer)
Caroline Dreuillet (Institut National du Cancer)
Eglys González‐Marcano (RUAG (Germany), International Society for Optics and Photonics) - ORCID: https://orcid.org/0000-0002-8825-0930
Olga Millán (RUAG (Germany), International Society for Optics and Photonics) - ORCID: https://orcid.org/0000-0002-6861-5832
Ulrich Jäger (Medical University of Vienna) - ORCID: https://orcid.org/0000-0001-9826-1062
Julio Delgado (Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer) - ORCID: https://orcid.org/0000-0002-5157-4376
Maik Luu (Augenklinik Universitätsklinikum Würzburg) - ORCID: https://orcid.org/0000-0003-2843-3919
Barbara Huber (Augenklinik Universitätsklinikum Würzburg)
Margot Lorrain (University of Luxembourg, Luxembourg Institute of Science and Technology, Arbed (Luxembourg))
Mariana Pina (University of Luxembourg, Luxembourg Institute of Science and Technology, Arbed (Luxembourg))
Andreas Kremer (University of Luxembourg, Luxembourg Institute of Science and Technology, Arbed (Luxembourg)) - ORCID: https://orcid.org/0000-0003-1466-0600
Natacha Bolaños (HOPE Clinic, Lymphoma Study Association)
Solène Clavreul (European Federation of Allergy and Airways Diseases Patients Associations) - ORCID: https://orcid.org/0000-0001-5384-8425
Samantha Nier (Advocates for Youth) - ORCID: https://orcid.org/0009-0000-9885-8766
R. D. Liu (Amsterdam Neuroscience, Amsterdam University Medical Centers, International Myeloma Foundation, Cancer Center Amsterdam, University of Amsterdam)
Birgit I. Lissenberg‐Witte (Vrije Universiteit Amsterdam) - ORCID: https://orcid.org/0000-0001-9448-1826
Sébastien Anguille (Antwerp University Hospital) - ORCID: https://orcid.org/0000-0002-1951-6715
Marie Robin (Université Paris Cité, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis, Cellular Therapeutics (United Kingdom), European Society for Blood and Marrow Transplantation) - ORCID: https://orcid.org/0000-0003-1388-9876
Emma Morris (University College London Hospitals NHS Foundation Trust, Institute of Infection and Immunity, University College London) - ORCID: https://orcid.org/0000-0003-4834-1130
Anna Sureda (Institut d'Investigació Biomédica de Bellvitge, Institut Català d'Oncologia) - ORCID: https://orcid.org/0000-0002-1238-6970
Marie Préau (Inserm, Groupe de Recherche en Psychologie Sociale, Délégation Régionale Auvergne-Rhône-Alpes) - ORCID: https://orcid.org/0000-0002-6239-1671
Myriam Pannard (Inserm, Groupe de Recherche en Psychologie Sociale, Délégation Régionale Auvergne-Rhône-Alpes) - ORCID: https://orcid.org/0000-0003-4898-1306
Geertruida H. de Bock (University Medical Center Groningen) - ORCID: https://orcid.org/0000-0003-3104-4471
Scott Wagers (Erasmus Hospital, FIT Consulting (Italy))
Hélène Trebeden‐Negre (Institut de Relations Internationales et Stratégiques)
Delphine Maucort‐Boulch (Université Claude Bernard Lyon 1, Centre National de la Recherche Scientifique, Hospices Civils de Lyon, Laboratoire de Biométrie et Biologie Evolutive) - ORCID: https://orcid.org/0000-0003-0042-7787
Michael Hudecek (Universitäts-Kinderklinik Würzburg, Augenklinik Universitätsklinikum Würzburg, Koenig & Bauer (Germany), National Center for Tumor Diseases, Fraunhofer Institute for Cell Therapy and Immunology) - ORCID: https://orcid.org/0000-0002-2280-2202
Carin A. Uyl‐de Groot (Erasmus University Rotterdam) - ORCID: https://orcid.org/0000-0001-5808-302X
Marie José Kersten (Amsterdam Neuroscience, Amsterdam University Medical Centers, International Myeloma Foundation, Cancer Center Amsterdam, University of Amsterdam) |
|
Point of Contact
|
Use email button above to contact.
LIST QDKM (LIST) |
|
Description
| Patient-reported outcomes (PROs) give direct insights into the treatment's impact on patient's life and complement clinical outcomes. However, since the advent of chimeric antigen receptor T-cell therapy (CAR-T), PROs have been underreported. Particularly, little is known about long-term health-related quality of life (HRQoL) and dimensions such as mental- and social well-being, working life, and financial burden. Therefore, we evaluated multidimensional PROs in a cross-sectional study among European patients who received CAR-T for hematologic malignancies. Patients completed validated questionnaires (EQ-5D-5L/EORTC-QLQ-C30/PCL-5/modified-iPCQ) and ad hoc items on treatment experiences, unmet care needs, and HRQoL. The survey was available online (January–October 2023) in 7 languages. Outcomes were compared with the European general population, a matched CAR-T–naive cohort with hematologic malignancies and across subgroups, using established thresholds for clinically important differences/problems and regression models. From 10 European countries, 389 patients participated (>1 year post-CAR-T: 56%). Mean EQ-VAS was 73.1 (standard deviation, 18.5). HRQoL was similar or better than reference cohorts, except for role-, social-, and cognitive-functioning. Physical-functioning problems were most frequently reported (41%), particularly by women, older individuals, and those who experienced neurotoxicity. The latter subgroup also reported more cognitive- and social-functioning problems. Anxiety regarding disease recurrence (76%), infections (66%) and long-term side effects (59%) was common. Among working-age patients, 72% could continue paid work after CAR-T. Younger patients (32%) reported more financial difficulties than older patients (9%). This study shows favorable general HRQoL after CAR-T compared with reference cohorts. However, a notable proportion of patients experienced problems in physical-, mental- and social well-being. We identified high-risk subgroups and care needs that should be addressed during follow-up. (2025-09-24)
***This entry has been automatically imported via OpenAlex by LIST harvest scripts. Please refer to https://doi.org/10.1182/bloodadvances.2025017081 for the original and latest version of the publication*** (2026-07-01) |
|
Subject
| Medicine, Health and Life Sciences |
|
Keyword
| Quality of life (healthcare)
Cohort
Anxiety
Disease
Cohort study
MEDLINE
Depression (economics) |
|
Topic Classification
| CAR-T cell therapy research
Cancer-related cognitive impairment studies
Frailty in Older Adults |
|
Deposit Date
| 2025-09-24 |
|
Data Type
| Article |
|
Data Source
| Blood Advances |